Who should be taking weight-loss drugs? Doctors share best candidates
Weight-loss drugs continue to grow in popularity, with market researchers predicting that global demand for the medications could reach $150 billion by 2035.
GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — are intended to treat type 2 diabetes and obesity.
Recent studies, however, have linked these medications to additional benefits, such as a reduction in heart disease and dementia risk, as doctors recommend them to a growing number of patients.
Scientists May Have Discovered Why The Pounds Come Back After Losing Weight
Even so, recent Yale research found that only 3% of eligible adults received a prescription.
Most adults who have obesity are good candidates for these medications, according to Dr. John Anderson, an internal medicine physician and diabetes specialist at the Frist Clinic in Nashville, Tennessee.
Read On The Fox News App
"However, the most important group that we really want to address are the patients who have obesity alongside other comorbid conditions, such as type 2 diabetes, hypertension, obstructive sleep apnea and significant osteoarthritis," Anderson, who is also a board member of the Diabetes Leadership Council, told Fox News Digital.
"Anyone who wants to lose weight who is obese is a good candidate, but from a medical standpoint, we're most concerned about this higher-risk patient population."
Study Directly Compares Zepbound And Wegovy For Weight-loss Results
To qualify for a weight-loss drug, the patient should first work with a physician to make lifestyle changes in the areas of diet, exercise, sleep and stress management, according to Dr. Michael Aziz, a board-certified internist and regenerative medicine specialist based in New York City.
"A healthy, balanced diet with plenty of vegetables and low-sugar fruits should be the first step in weight loss," he told Fox News Digital.
"But some people, despite their best efforts, can't lose weight. This could be related to injuries that prevent them from working out or a slow metabolism."
Insurance pays for weight-loss medications if the patient's body mass index is over 27, according to Aziz.
(Patients are considered overweight if they have a BMI of 25 to 29.9, and are considered obese if the number is greater than 30, according to the National Institutes of Health.)
Beyond the high-risk groups, Anderson said he'd like to see these medications made "available and affordable" for a vast majority of patients impacted by obesity.
"By treating obesity earlier, we can prevent disease progression," he said. "GLP-1s have been shown to reduce progression from prediabetes to type 2 diabetes by 94%, and significantly reduce the risk of major cardiovascular events."
He added, "Obesity is connected to 200 comorbidities, including heart disease, kidney disease and 40% of all cancers, which is why addressing the disease early is key."
Doctors Warn Of 'Trifecta' Of Chronic Illnesses Plaguing Americans After Maha Report
Patients don't have to be diabetic to benefit from GLP-1 medications for weight loss, according to Dr. Wiljon Beltre, a board-certified bariatric and metabolic surgeon and the founder of Beltre Bariatrics in Orlando, Florida.
"I also agree that patients with lower levels of obesity (BMI lower than 30) can derive great benefits from these medications," he told Fox News Digital.
"These patients can turn out to be excellent candidates for GLP-1s, since they seem to lose weight faster and notice a change almost immediately."
Several ongoing studies are exploring the use of weight-loss medications to treat a range of conditions, including alcoholism and addiction, Alzheimer's and dementia, liver disease, and more, according to Anderson.
"The way these medications work is by slowing stomach emptying so that you feel fuller longer, but they also have feedback to the appetite center of hypothalamus in the brain, which turns off the food noise," he said.
"Experts across the country are finding that it also seems to reduce cravings for alcohol in patients — that their reward center is turning off the desire for alcohol."
More research is needed to confirm this effect, but Anderson said these drugs could potentially be "life-changing" for those battling addiction.
Weight-loss Medications May Also Benefit Common Medical Problem, Study Finds
Aziz noted that GLP-1 drugs have also been shown to reduce the risk of both heart attacks and stroke by 20%.
"They also help to reverse a fatty liver and improve sleep apnea," he added.
Diabetes and obesity medications are widely known to cause gastrointestinal issues in some patients — primarily nausea, with some reporting vomiting, constipation and diarrhea.
"Most of those occur when doing dose escalation, and the vast majority are able to get through that," Anderson said. "This typically occurs early in therapy and tapers off over time."
Patients with a family history of medullary thyroid cancer or pancreatitis should avoid these medications, according to experts. Pregnant women are also advised against taking them.
Some patients have also reported a loss of muscle mass, hair thinning or shedding, mood changes and other unwanted outcomes.
Click Here To Sign Up For Our Health Newsletter
"People should understand that GLP-1 is not a magic solution to weight loss, but one leg of a three-legged stool — it needs to be combined with healthy eating habits and exercise," said Beltre.
It's also important for patients to understand that they cannot take these medications forever, the doctor noted.
Many doctors, however, report that the benefits outweigh the potential side effects.
"Importantly, I'm seeing many patients now able to participate in activities for the first time in many years following significant weight loss — ice skating, going on walks, canceling knee replacements and dropping blood pressure medications," Anderson noted.
For more Health articles, visit www.foxnews.com/health
Those interested in weight-loss medications should consult with a physician to explore potential benefits and risks.Original article source: Who should be taking weight-loss drugs? Doctors share best candidates
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Study: Real-world results of GLP-1 drugs don't match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says. People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity. That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said. "Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial," lead investigator Hamlet Gasoyan said in a news release. He is a researcher at the Cleveland Clinic Center for Value-Based Care Research. People taking the drugs in real-world settings appear to be more likely to quit taking the meds, researchers said. They also might be prescribed lower dosages in clinical practice than were used in the drug trials. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide. Average body weight loss after a year was nearly 9% for the whole group, results show. But weight loss varied based on when a person stopped taking the drugs, researchers found. Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says. Those who stayed on their medications lost an average 12% body weight. Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well. People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide. "Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Gasoyan said. Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show. The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said. Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a person's risk of developing Type 2 diabetes. About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier. "Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important," Gasoyan said. "This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes." A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said. More information Harvard Medical School has more on GLP-1 drugs. Copyright © 2025 HealthDay. All rights reserved.


The Hill
2 hours ago
- The Hill
Lawmakers urge Trump administration to clamp down on illicit GLP-1 sales
A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing these drugs without knowing the product could be fraudulent. North Carolina Reps. Brad Knott (R) and Deborah Ross (D) wrote to Food and Drug Administration (FDA) Commissioner Marty Makary, Homeland Security Secretary Kristi Noem and U.S. Attorney General Pam Bondi, imploring them to end the sale of 'counterfeit, research-grade and illegal copycats' of popular GLP-1 medications. When the commercial, branded versions of tirzepatide and semaglutide were declared to no longer be in shortage, compounding pharmacies were disallowed from continuing to sell compounded versions of those drugs. While telehealth companies have transitioned away from compounded versions, state officials have warned that 'copycat' drugs have proliferated in the months since the shortages ended. Earlier this year, the National Association of Attorneys General sent a letter to the FDA to warn that 'counterfeit GLP-1 drugs have infiltrated the U.S. supply chain from China, Turkey, India, and other foreign sources.' According to the attorneys general, online retailers sell the active ingredient for the GLP-1s under the claim that they're 'for research purposes only' or 'not for human consumption' while still marketing them to consumers on social media. The FDA issued a warning in April, telling consumers to not take counterfeit Ozempic. The drug's manufacturer, Novo Nordisk, had alerted the agency that several hundred units of counterfeit product had entered the U.S. supply chain. At the time, the FDA said it was aware of six adverse events associated with the counterfeit products. Though the FBI issued a public service warning soon after the letter from the attorneys general was sent, Knott and Ross said raising public awareness wasn't enough. 'FDA has received hundreds of reports of adverse events, even some resulting in the hospitalization and death of patients who used illicit GLP-1s,' they wrote. 'This is likely a significant underreporting of adverse events experienced by patients because federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA.' The lawmakers asked that the Trump Cabinet members fully use 'the legal tools at your discretion' to further detect illicit and enforce U.S. drug standards. Sen. Thom Tillis (R-N.C.) sent his own letter to Cabinet members, calling for enhanced collaboration among agencies like FDA, U.S. Customs and Border Protection and the Justice Department in order to stop the counterfeit products from reaching the supply chain in the first place. The Hill has reached out to the agencies named in the letter for comment.
Yahoo
3 hours ago
- Yahoo
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Eli Lilly's LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than three years. Mounjaro and Zepbound include the same compound tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company's total revenues. Both drugs enjoy increasing market share in the United States. Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025, driven by launches of the drugs in new international markets and improved supply from ramped-up production. Since 2020, Lilly has committed more than $50 billion to manufacturing capacity for its drugs, mainly Zepbound and Mounjaro, in the United States and Europe. We believe that increased uptake in outside U.S. markets and deeper penetration into the U.S. market will continue to drive Mounjaro and Zepbound's growth in future quarters. Our model estimates combined Mounjaro and Zepbound sales of $48.2 billion by 2027. Approvals for new indications can also drive sales of Mounjaro and Zepbound higher. In late December, the FDA approved Zepbound for its second indication, moderate-to-severe obstructive sleep apnea in adults with obesity. In addition, LLY filed tirzepatide for heart failure, which further expands the opportunity for the candidate. It also expects to announce data from a cardiovascular outcome study on tirzepatide this year. The obesity market is heating up and is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk's semaglutide medicines, Ozempic for diabetes and Wegovy for obesity. Several companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and type II diabetes, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Phase III studies with the subcutaneous formulation of VK2735 are on track to begin this year. Others like Roche, Merck and AbbVie are also looking to enter the obesity space by in-licensing obesity candidates from smaller biotechs, which could threaten Novo Nordisk and Eli Lilly's dominance in the market. Lilly's stock has risen 5% so far this year compared with the industry's increase of 0.6%. Image Source: Zacks Investment Research From a valuation standpoint, Lilly's stock is expensive. Going by the price/earnings ratio, the company's shares currently trade at 31.21 forward earnings, higher than 15.17 for the industry. However, the stock is trading below its 5-year mean of 34.54. Image Source: Zacks Investment Research Estimates for Lilly's 2025 earnings have declined from $23.49 to $21.95 per share in the past 60 days, while those for 2026 have declined from $31.28 to $30.91 over the same timeframe. Image Source: Zacks Investment Research Lilly has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data